Metraipolis › archive › dc_e6dfb2750ff3

Nonmyeloablative pentostatin-cyclophosphamide preconditioning improves rates of engraftment in adults undergoing haploidentical HCT for sickle cell disease — Europe PMC PMID:41871072

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41871072
DOI
10.1371/journal.pone.0332282
License (as archived)
CC0-1.0
Archived
2026-10-06T08:18:58.537Z
SHA-256 of the archived text
ea9f95f4569db1e298bb7431c27b6d7ee447f179a7dd4abeb4ab9bde0fc76e15
Stable URL of this page
https://metraipolis.com/documento/dc_e6dfb2750ff3

How to cite

Nonmyeloablative pentostatin-cyclophosphamide preconditioning improves rates of engraftment in adults undergoing haploidentical HCT for sickle cell disease — Europe PMC PMID:41871072 — Europe PMC (en), https://europepmc.org/article/MED/41871072 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_e6dfb2750ff3 (Metraipolis archive dc_e6dfb2750ff3, sha256 ea9f95f4569db1e298bb7431c27b6d7ee447f179a7dd4abeb4ab9bde0fc76e15)
BibTeX
@misc{dce6dfb2750ff3,
  title = {Nonmyeloablative pentostatin-cyclophosphamide preconditioning improves rates of engraftment in adults undergoing haploidentical HCT for sickle cell disease — Europe PMC PMID:41871072},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41871072},
  note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_e6dfb2750ff3; sha256 ea9f95f4569db1e298bb7431c27b6d7ee447f179a7dd4abeb4ab9bde0fc76e15},
  year = {2026}
}

Archived text

Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/41871072. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

The morbidity and mortality of sickle cell disease (SCD) remain high. Novel nonmyeloablative haploidentical hematopoietic cell transplant (HCT) regimens are being proposed. Methods: This report compared the effect of adding an IV pentostatin and oral cyclophosphamide (PC) preconditioning to the nonmyeloablative NIH HCT platform of alemtuzumab and total body irradiation (TBI) in adults with severe SCD. Transplant outcomes were compared to a historical HCT cohort that did not receive the PC preconditioning. Results: Thirty-nine adult SCD patients were included. The median age was 33 years, 61% were male, and 92% were HbSS genotype. The median follow-up was 6.5 years. Many patients had severe end-organ damage, including dialysis-dependent end-stage kidney disease (8%) and cirrhosis (10%). One-year overall survival was 95%. The PC regimen was associated with a reduction in acute rejection one-year post-HCT (5% vs. 44%; p = 0.004) and lower graft failure rates throughout the follow-up period. After a median follow-up of 5.2 years, the disease-free survival was 71% for the PC regimen. The PC preconditioning was associated with higher rates of full donor chimerism at 2-years post-HCT (0% vs. 43%; p = 0.02). Grade II-IV acute graft-versus-host disease (GVHD) rates were low; no patients developed moderate to severe chronic GVHD. There remain no cases of myeloid malignancy after PC. With the increased immunosuppression of PC, 23% of patients developed post-transplant lymphoproliferative disorder, 19% developed immune cytopenias, and 62% had viral reactivation. Summary: Further study to determine an optimal nonmyeloablative haploidentical regimen for SCD patients with compromised organ function is imperative. Clinical trial registry: ClinicalTrials.gov (NCT00977691, NCT03077542).

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera).
Pubblicazione: PloS one, 2026 (prima pubblicazione 2026-03-23).
Identificativi: PMID 41871072 · PMCID PMC13008046 · DOI 10.1371/journal.pone.0332282.
Descrittori MeSH principali: Anemia, Sickle Cell; Cyclophosphamide; Pentostatin; Transplantation Conditioning; Hematopoietic Stem Cell Transplantation.
Pagina: https://europepmc.org/article/MED/41871072 — https://doi.org/10.1371/journal.pone.0332282. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito).
Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0.
Letto il 2026-10-06T08:18:30.375Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.